Elutia Inc.
ELUT Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.84
KIRA · Stoqly’s AI analyst, in plain words
- Elutia Inc. had $12.3M of revenue in fiscal 2025, down 15.0% on the year before. Over five years, revenue changed −22.0% a year on average.
- Its operating margin was −218.9%, down 6.6 pts: of every 100 in sales, about −219 is left after running the business.
- Elutia Inc. made $53.4M of net profit in fiscal 2025.
- Free cash flow was −$46.7M in fiscal 2025, −379.8% of revenue.
Market cap
$37.0M
P/E
0.8x
Revenue
$12.3M
Net income
$53.4M
Free cash flow
−$46.7M
Operating margin
−218.9%
Elutia Inc. in 30 seconds · fiscal 2025
Are sales growing?
−15.0%
No. Sales fell 15.0% last year.
Does it make a profit?
434.2%
Yes. It keeps 434.2% of every sale as profit.
Does profit turn into cash?
−379.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
0.8x
One share costs 0.8 times its yearly profit per share.
What Elutia Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 13, 2026
- Legal name
- ELUTIA INC.
- CIK
- 0001708527
Elutia Inc. · ELUT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $47.4M | $23.8M | $24.7M | $14.5M | $12.3M |
| Revenue growth | 11.0% | −49.7% | 3.8% | −41.5% | −15.0% |
| Gross margin | 40.1% | 48.8% | 44.7% | 46.4% | 53.7% |
| Operating margin | −48.6% | −147.5% | −123.4% | −212.3% | −218.9% |
| Net income | −$24.8M | −$32.9M | −$37.7M | −$53.9M | $53.4M |
| Net margin | −52.4% | −137.9% | −152.2% | −372.9% | 434.2% |
| Diluted EPS | −$2.38 | −$2.38 | −$2.07 | −$1.86 | $0.87 |
| Cash | |||||
| Cash from operations | −$15.4M | −$21.4M | −$21.8M | −$22.7M | −$44.8M |
| Capital expenditure | $0.4M | $0.5M | $0.3M | $0.7M | $1.9M |
| Free cash flow | −$15.8M | −$22.0M | −$22.1M | −$23.3M | −$46.7M |
| FCF margin | −33.4% | −92.1% | −89.3% | −161.1% | −379.8% |
| Share count change | 266.2% | 32.4% | 31.3% | 60.1% | 58.0% |
| Debt and strength | |||||
| Cash and short-term investments | $30.4M | $17.0M | $19.3M | $13.2M | $36.4M |
| Debt incl. finance leases | $26.5M | $24.3M | $27.0M | $25.1M | — |
| Shareholders' equity | $13.5M | −$5.0M | −$38.6M | −$46.3M | $27.7M |
| Current ratio | 1.8x | 1.2x | 0.7x | 0.7x | 2.2x |
| Interest coverage | −4.3x | −6.9x | −5.3x | −6.4x | — |
| Returns and quality | |||||
| Return on capital | −188.4% | −1,242.1% | — | — | — |
| Return on equity | −144.6% | −775.1% | — | — | — |
| Return on tangible equity | — | — | — | — | 0.2% |
| Piotroski F-score | 2 | 3 | 2 | 2 | 4 |
| Altman Z'' | −5.0 | −9.3 | −20.2 | −29.1 | −8.0 |
Insiders bought, 12 months
$0.2M
7 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Elutia Inc. · ELUT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.84 a share, the company is worth $37.0M: 0.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001708527). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.